This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	<i>AT rich interactive domain 1A (ARID1A)</i>	<p>A study in patient samples suggests that mutations in <i>ARID1A</i> could contribute to ovarian clear cell carcinoma and might be disease markers. Whole-transcriptome sequencing of 18 ovarian clear cell carcinoma patient samples showed that 33% had mutations in <i>ARID1A</i>. DNA sequencing of <i>ARID1A</i> in 228 patient tumor samples showed that 46% of ovarian clear cell carcinomas and 30% of endometrioid carcinomas had mutations in <i>ARID1A</i>. Next steps include further study of how mutations in <i>ARID1A</i> contribute to endometrial cancer.</p> <p>SciBX 3(38); doi:10.1038/scibx.2010.1150 Published online Sept. 30, 2010</p>	Patent application filed; available for licensing from the BC Cancer Agency Technology Development Office	<p>Wiegand, K.C. <i>et al. N. Engl. J. Med.</i>; published online Sept. 8, 2010; doi:10.1056/NEJMoa1008433</p> <p>Contact: David G. Huntsman, BC Cancer Agency, Vancouver, British Columbia, Canada e-mail: dhuntsma@bccancer.bc.ca</p>